

## **CarThera to present update on SonoCloud-9 clinical study at upcoming SNO Congress in Phoenix, Arizona**

**Company recently received FDA approval for clinical trial; next generation device, SonoCloud-9, will soon be trialed in US**

**Paris, France, November 14, 2019** – CarThera, a French company that designs and develops innovative ultrasound-based medical devices to treat brain disorders, will attend the the Society for Neuro-Oncology's (SNO) [24th Annual Meeting](#), in Phoenix, Arizona, November 20-24. Professor Alexandre Carpentier, founder of CarThera and neurosurgeon at Pitie Salpetriere Hospital (Paris, France), will be presenting an update on CarThera's on-going work to develop the SonoCloud for treatment of brain tumors.

As the world's largest neuro-oncology conference, the event attracts over 2,400 researchers and clinician scientists from more than 40 countries worldwide. CarThera will join delegates to share its own medical knowledge and gain insights on the future of neuro-oncology research and treatment.

The SNO Annual Meeting plays a vital role in bridging the gap between neuro-oncology research and clinical practice, with medical experts coming together to discuss a detailed scientific program that will center around 'Innovation to Overcome Tumor Resistance'.

CarThera's low-intensity pulsed ultrasound device, SonoCloud, is one of the major innovations in the field. It is designed to temporarily open the blood-brain barrier (BBB), potentially improving the penetration of therapeutic agents into the brain to increase efficacy and overcome tumor resistance.

The company recently reported the results of a [Phase 1/2a glioblastoma trial](#) in France (Sorbonne University-Pitie Salpetriere Hospital at AP-HP) with its first generation device, the SonoCloud-1. At SNO, on Saturday, November 23, Professor Alexandre Carpentier will provide an update on the ongoing SonoCloud-9 trial. Before that, on Thursday, November 21, he will also present an invited talk on 'Ultrasound Enabled Drug Delivery' at a special 2-day joint SNO-SCIDOT (Society for CNS Interstitial Delivery of Therapeutics) session prior to the conference.

"Following this summer's FDA approval for the SonoCloud-9 clinical trial in recurrent glioblastoma, we are delighted to present our latest work at this important meeting," said Professor Alexandre Carpentier. "In addition to my talk at the SNO-SCIDOT special session on therapeutic delivery to the central nervous system, there are numerous other talks on the topic of using ultrasound, showing the growing interest in use of this technology among clinicians."

"Our new generation device, the SonoCloud-9, is under clinical trial in France and will soon be trialed in the US at the MD Anderson Cancer Center in Houston and the Northwestern Memorial Hospital in Chicago," said Frédéric Sottolini, CEO of CarThera. "This study, conducted by Professor Ahmed Idbaih, is a first step in the development of the SonoCloud-9 for glioblastoma. A pivotal trial should start at the end of 2020 in Europe and the US."

### **About the Society for Neuro-Oncology**

The SNO is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education.



Now in its 24th year, the society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other healthcare professionals whose focus is central nervous system (CNS) tumors in children and adults.  
[www.soc-neuro-onc.org](http://www.soc-neuro-onc.org)

### **About CarThera**

CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders. The company is a spin-off from AP-HP, Greater Paris University Hospitals, the largest hospital group in Europe, and Sorbonne University. Since 2010, CarThera has been leveraging the inventions of Professor Alexandre Carpentier, a neurosurgeon at AP-HP who has achieved worldwide recognition for his innovative developments in treating brain disorders. CarThera developed SonoCloud, an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB).

CarThera is based at the Brain and Spine Institute (Institut du Cerveau et de la Moelle épinière, ICM) in Paris, France, and has laboratories at the Bioparc Laënnec business incubator in Lyon, France. The company, led by Frederic Sottolini (CEO), works closely with the Laboratory of Therapeutic Applications of Ultrasound (Laboratoire Thérapie et Applications Ultrasonores, LabTAU, INSERM) in Lyon.

[www.carthera.eu](http://www.carthera.eu)

### **Media contacts**

Andrew Lloyd & Associates  
Jo Reeder / Juliette Schmitt-dos Santos  
[jo@ala.com](mailto:jo@ala.com) - [juliette@ala.com](mailto:juliette@ala.com)  
Tel: +44 1273 675 100  
@ALA\_Group